# Arrowhead Pharmaceuticals Inc. (ARWR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $9.84B  
**Price:** $73.60 (+4.06%)

> Arrowhead Pharmaceuticals is a biotechnology company focused on developing innovative medicines for intractable diseases. The company specializes in RNA interference (RNAi) therapeutics, a cutting-edge approach to treating genetic and metabolic disorders by targeting disease-causing proteins at the molecular level. Its pipeline includes several clinical-stage candidates addressing significant unmet medical needs, such as Plozasiran for cardiovascular disease, Zodasiran for lipid disorders, and ARO-INHBE for metabolic dysfunction-associated liver disease. The company also develops investigational therapies targeting conditions including chronic kidney disease, obesity, and neurodegenerative diseases. Arrowhead operates in the growing biotechnology sector, where it competes alongside other drug developers pursuing advanced therapeutic approaches. Founded in 2003 and headquartered in the United States, Arrowhead represents the emerging class of precision medicine companies leveraging molecular biology to address diseases that traditional pharmaceuticals have struggled to treat effectively.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $829M | — | $98M | -$2M | — |
| 2024 | $4M | — | -$601M | -$599M | — |
| 2023 | $241M | — | -$205M | -$205M | — |
| 2022 | $243M | — | -$179M | -$176M | — |
| 2021 | $138M | — | -$149M | -$141M | — |
| 2020 | $88M | — | -$93M | -$85M | — |
| 2019 | $169M | — | $61M | $68M | — |
| 2018 | $16M | — | -$56M | -$54M | — |
| 2017 | $31M | — | -$37M | -$34M | — |
| 2016 | $158,333 | — | -$82M | -$82M | — |
| 2015 | $382,000 | — | -$96M | -$92M | — |
| 2014 | $175,000 | — | -$53M | -$59M | — |
| 2013 | $290,266 | — | -$25M | -$31M | — |
| 2012 | $146,875 | — | -$21M | -$21M | — |
| 2011 | $296,139 | — | -$10M | -$3M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $1.39B | $919M | $466M | — | — |
| 2024 | $1.14B | $954M | $185M | — | — |
| 2023 | $766M | $494M | $271M | — | — |
| 2022 | $692M | $293M | $399M | — | — |
| 2021 | $710M | $301M | $409M | $184M | — |
| 2020 | $523M | $61M | $462M | $144M | — |
| 2019 | $350M | $105M | $245M | $222M | — |
| 2018 | $112M | $16M | $96M | $30M | — |
| 2017 | $104M | $23M | $81M | $25M | — |
| 2016 | $128M | $33M | $96M | $85M | — |
| 2015 | $132M | $22M | $110M | $81M | — |
| 2014 | $183M | $16M | $167M | $133M | — |
| 2013 | $37M | $10M | $27M | $19M | — |
| 2012 | $17M | $7M | $10M | $3M | — |
| 2011 | $16M | $3M | $13M | $8M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | $180M | $23M | $157M |
| 2024 | -$463M | $141M | -$604M |
| 2023 | -$154M | $177M | -$331M |
| 2022 | -$136M | $53M | -$189M |
| 2021 | $171M | $24M | $148M |
| 2020 | -$96M | $12M | -$108M |
| 2019 | $173M | $12M | $161M |
| 2018 | -$47M | $1M | -$49M |
| 2017 | -$24M | $8M | -$32M |
| 2016 | -$64M | $4M | -$68M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ARWR)